Dr Merav Bassan, PhD., serves as Chief Development Officer at BiomX, a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria in multiple diseases. In her role Dr Bassan oversee the R&D organization including research, development, GMP manufacturing, bioinformatic and the clinical team.
Previously Dr. Bassan was Vice President Head of Translational Sciences at Teva pharmaceutical responsible for early stages of clinical development via translation from animal data to human using pharmacologic, bioinformatic and data science tools. Prior to this role Dr Bassan served as VP project leadership, leading project leaders overseeing drug development end to end including pre-clinical, PI-III and post marketing in multiple areas of development such as pain, oncology, woman health, endocrinology, GI, biosimilar etc. Additionally Dr Bassan led teams in both clinical department and overall drug development for over 20 years in Teva pharmaceutical and smaller biotech. Dr Bassan is also a member of the 8400 health network in Israel a cross-sector leaders’ network actualizing the globally disruptive capability of Israel’s HealthTech ecosystem.
Dr Bassan graduated her Ph.D. from Tel-Aviv University, Sackler medical school, clinical biochemistry department focusing on neuroscience and a post-doctoral fellowship at Harvard University Boston in Neuroscience.